Niagen Bioscience, Inc. (NAGE)
Official siteCONSUMER DEFENSIVE • BIOTECHNOLOGY • NASDAQ
Market Cap: $163.54M
Last updated: Nov 17, 2026 at 11:03 AM ET
Niagen Bioscience, Inc. (NAGE) P/E Ratio & Valuation History
Niagen Bioscience (NAGE) trades at 42.2x trailing earnings and 1.3x sales. Its P/S of 1.3x is below its 5-year median of 2.4x. Its forward P/E is 41.1x. The median P/E across 7 similar companies is 11.1x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 2.7% higher over the next year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 42.2x |
| Forward P/E | 41.1x |
| Price to sales | 1.3x |
| Price to book | 1.9x |
| EV/EBITDA | 8.4x |
| PEG | N/A |
Historical Medians
Against its 10-year medians, its P/S is 71.1% below 4.5x and its P/B is 74.7% below 7.5x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 1.3x | 2.4x | 4.5x |
| P/B | 1.9x | 5.5x | 7.5x |
Valuation History
Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 1.3x in 2023 to 6.0x in 2018.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $6.36 | 37.9x | 3.9x | 7.0x |
| 2024 | $5.31 | 45.9x | 4.1x | 9.4x |
| 2023 | $1.43 | N/A | 1.3x | 3.8x |
| 2022 | $1.68 | N/A | 1.6x | 5.5x |
| 2021 | $3.74 | N/A | 3.7x | 7.2x |
| 2020 | $4.80 | N/A | 4.9x | 15.2x |
| 2019 | $4.31 | N/A | 5.3x | 9.2x |
| 2018 | $3.43 | N/A | 6.0x | 5.7x |
| 2017 | $5.88 | N/A | N/A | N/A |
| 2016 | $3.31 | N/A | 5.7x | 10.6x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About NAGE
What is NAGE's forward P/E ratio?
Niagen Bioscience has a forward P/E ratio of 41.1x.
Is NAGE stock overvalued?
GNG's valuation label for NAGE is Fairly valued. Its P/E of 42.2x compares with a median of 11.1x across 7 similar companies.
What is NAGE's price to sales ratio?
Niagen Bioscience has a price to sales ratio of 1.3x.
NAGE pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors